You spend three years in your garage building a prototype. You file a patent application, the office grants it, and a manufacturer offers you $750,000 plus a 4% running royalty on every unit sold. Without planning, that money is ordinary income taxed at rates up to 37%. With the right contract language and one obscure provision of the tax code, the same dollars can drop into the 0%, 15%, or 20% long-term capital gains brackets—even if you finished the invention last Tuesday.
That obscure provision is Internal Revenue Code Section 1235, and it has quietly survived every major tax overhaul of the last decade. While the Tax Cuts and Jobs Act killed off favorable capital gain treatment for most self-created intangibles—copyrights, secret formulas, unpatented inventions—Section 1235 still gives patent holders a way to flip the entire transaction from ordinary income into long-term capital gain. The catch is narrow but precise: you must be the right kind of taxpayer, you must transfer the right kind of property, and you must give up the right kind of rights.
Most inventors, garage entrepreneurs, and early-stage investors do not realize this rule exists. The ones who do still get it wrong because their lawyers draft a "license" that the IRS treats as a license, not a sale. The drafting choices made in a single afternoon can change a seven-figure tax bill by hundreds of thousands of dollars.
This guide walks through who qualifies as a "holder," what "all substantial rights" really means, why the holding-period rule does not matter, how Section 1235 interacts with the post-TCJA carve-outs for self-created property, and the contract drafting choices that decide whether the IRS sees a sale or a royalty.
The Headline Benefit: Capital Gain Without a Holding Period
The normal rule for capital assets is that you must hold them for more than one year to qualify for long-term capital gain rates. Section 1235 throws that rule out the window for patents.
The statute says that a qualifying transfer of "all substantial rights to a patent, or an undivided interest therein which includes a part of all such rights, by any holder shall be considered the sale or exchange of a capital asset held for more than 1 year." The phrase "held for more than 1 year" is statutory fiction—Congress is telling the IRS to treat the transaction as long-term regardless of how briefly you actually owned the patent.
This matters because patents often get transferred quickly. The inventor finishes the prototype, files the application, and an industry buyer comes calling within months. Without Section 1235, the gain would be short-term, taxed at ordinary rates. With Section 1235, every dollar of gain is long-term, taxed at the preferential capital gains rate.
The benefit extends to the structure of payment. The transferee can pay you with:
- A single lump sum at closing
- Periodic payments stretched over the life of the patent
- Contingent payments tied to productivity, use, or disposition of the patent (a "running royalty")
All three structures still produce long-term capital gain under Section 1235. This is unusual. In most contexts, payments contingent on production look exactly like royalty income and get taxed as ordinary. Section 1235 explicitly overrides that intuition.
Who Counts as a "Holder"
Section 1235 only helps a "holder," and the definition is narrower than people assume. A holder must be an individual—not a corporation, not a partnership, not an LLC taxed as a corporation. Trusts and estates also fall outside.
There are exactly two paths to becoming a holder:
Path 1: The Creator. Any individual whose efforts created the patented property qualifies. This is the inventor named on the application, the person who reduced the invention to practice. A team of two co-inventors can each be a holder for their respective shares.
Path 2: The Early Investor. An individual who acquired an interest in the invention from the creator before the invention was actually reduced to practice, and who paid money or money's worth for it. Think of an angel funder who writes a check to a tinkerer with a half-built prototype.
Path 2 has two critical exclusions. The early investor cannot be the creator's employer—you cannot fund your own employee's work and then claim Section 1235 treatment when the patent sells. The early investor also cannot be related to the creator under a modified version of Section 267. The standard related-party rules apply, but the ownership threshold drops to 25% (instead of the usual 50%), and the family-member definition is restricted to spouses, ancestors, and lineal descendants. Siblings, aunts, uncles, and cousins do not count as related for Section 1235—which is unusual and worth noting.
A common trap: someone forms a single-member LLC and assigns the patent application to it. If the LLC is disregarded for tax purposes, the individual still qualifies as a holder. If the LLC elects corporate treatment, Section 1235 becomes unavailable. Entity choice in the early years of an invention has tax consequences that show up at exit.
The Self-Created Intangibles Problem and Why Section 1235 Survives It
In 2018, the Tax Cuts and Jobs Act changed Section 1221(a)(3) to exclude from the definition of a capital asset any "patent, invention, model or design (whether or not patented), or secret formula or process" held by the creator (or by a taxpayer whose basis in the property is determined by reference to the creator's basis).
Read plainly, this rule says that when an inventor sells a patent, the gain is ordinary income—not capital gain. That would have killed favorable treatment for nearly every garage inventor in the country.
But Congress did not amend Section 1235. The two sections now coexist in apparent tension, and practitioners have generally concluded that Section 1235 controls for patents specifically. The IRS has not challenged this view in published guidance, and the dominant interpretation in the tax literature is that Section 1235 provides an exception that allows patent sales by a holder to remain capital gain transactions, while sales of copyrights, models, designs, and unpatented inventions are now stuck with ordinary treatment.
The practical result is striking. If you write a novel and sell the copyright, your gain is ordinary income. If you invent a widget, patent it, and sell the patent, your gain is long-term capital gain. The economic activity is similar; the tax outcome is very different. Section 1235 carves out patents as a privileged category of self-created intellectual property.
This makes the decision to file a patent application a tax decision as much as a legal one. Inventors sometimes keep their work as trade secrets to avoid disclosure. Trade secrets are not patents, so they do not get Section 1235 treatment. The patent application itself is the entry ticket to favorable tax treatment of any eventual sale.
What "All Substantial Rights" Actually Means
This is where most Section 1235 deals fall apart. The statute requires transfer of "all substantial rights to a patent, or an undivided interest therein which includes a part of all such rights." If you transfer less than all substantial rights, the transaction is a license, the payments are royalties, and you are back in the ordinary income world.
Treasury Regulation 1.1235-2 spells out what is and is not substantial. The list of non-qualifying limitations is the part that matters in practice:
Geographic limits within the country of issuance. Granting a patent license that covers California only, or the eastern United States only, is not a transfer of all substantial rights. You can grant rights for multiple foreign countries, but slicing the United States into territorial regions kills capital gain treatment.
Time limits shorter than the remaining patent life. A patent typically has a 20-year life from filing. If your agreement runs for ten years and then reverts to you, you have not transferred all substantial rights. The grant must run for the full remaining life of the patent.
Field-of-use restrictions. Granting rights only for medical applications, or only for consumer electronics, or only for one specific industry, is a field-of-use limit. Even if the field is the patent's most valuable use, the limitation defeats Section 1235.
Partial claims or uses. A patent may cover multiple claims or multiple inventive concepts. Transferring rights to only some of the claims, while keeping others, is not a transfer of all substantial rights.
What you can keep:
- Legal title for security purposes. You can hold the title as collateral until the buyer finishes paying. The regulations treat this as a non-substantial right that the transferor can retain.
- An undivided fractional interest. You can transfer a 50% undivided interest in the patent—every claim, every field, every territory, every year. The buyer gets a co-ownership stake, which is treated as a transfer of all substantial rights "in an undivided interest."
The regulations say plainly that the IRS looks at the "circumstances of the whole transaction, rather than the particular terminology used in the instrument of transfer." Calling something an "exclusive license" instead of an "assignment" does not save it if you have actually transferred everything. Calling something an "assignment" does not save it if you have actually retained meaningful sticks from the bundle.
How to Structure a Section 1235 Deal That Holds Up
If you want capital gain treatment, the agreement should look and feel like a sale. Several drafting choices matter:
Use sale language, not license language. "Assignment of all right, title, and interest in and to the patent, including the right to sue for past, present, and future infringement" is sale language. "Exclusive license to make, use, and sell" is license language. The IRS reads both, but starting with sale language puts you on the right side of the line.
Transfer all claims, all fields, all geographies, all time. Write the operative grant clause to cover everything the patent covers. Resist the temptation to slice and dice. If the buyer wants narrower rights, consider a different structure entirely—you cannot have Section 1235 treatment on partial transfers.
Let the buyer enforce the patent. Suing infringers is one of the most valuable rights in the patent bundle. If you reserve enforcement rights, the IRS may say you kept a substantial right. The buyer should have unilateral authority to sue, settle, and license to others.
Allow the buyer to sublicense. A right to sublicense is part of the bundle. If you forbid sublicensing, you are limiting the transferred rights.
Don't reserve approval rights over the buyer's decisions. If you can veto the buyer's decision to abandon, modify, or relicense, the IRS may see you as still controlling the property.
Document the running royalty as the price. When the agreement includes contingent payments, make sure the contract characterizes them as the consideration for the sale, not as ongoing royalties. The economic substance is the same—your tax treatment depends on the formal characterization.
Reporting the Income on Your Return
For an inventor, this is the part that confuses tax software. The buyer will likely issue a Form 1099-MISC reporting the payments as royalties in Box 2, because that is the buyer's tax department's default treatment. The 1099 form does not control how you report the income.
If your transaction qualifies under Section 1235, you report the gain on Schedule D and Form 8949 as a long-term capital gain. Describe the property as the patent, list your basis (usually low—out-of-pocket prosecution costs, drawings, prototypes), and report the proceeds.
If the agreement involves contingent or periodic payments, you have a few choices:
- Closed transaction method. Estimate the present value of expected payments at closing and report the entire gain in the year of sale, treating later receipts as recovery of basis or additional gain.
- Open transaction method. Report each payment as it arrives, treating each one as the sale of a fractional interest in the patent. This is administratively simpler and is the most common approach for genuinely uncertain royalty streams.
What you should not do is dump the income onto Schedule E as royalty income. Schedule E is for licensors who retained substantial rights. If you file Schedule E for a Section 1235 transaction, you have effectively conceded ordinary income treatment, and a later attempt to amend may not succeed.
If the IRS challenges the characterization, you will need contemporaneous evidence: the assignment agreement, evidence that you no longer control the patent, evidence that the buyer practices the invention without restriction, and the prosecution file showing you are the named inventor.
Estate Planning and the Holder's Heirs
The statute says a "holder" includes the original inventor or qualifying early investor. The Treasury Regulations extend Section 1235 treatment to the heirs of a holder—someone who inherits the patent steps into the holder's shoes and can sell under Section 1235.
This is important for estates that include unmonetized patents. If the inventor dies before licensing or selling the patent, the heirs can still claim Section 1235 treatment when they transfer the patent. The basis step-up at death also applies, so heirs often pay very little capital gains tax on a sale because both the favorable rate and the stepped-up basis work in their favor.
The exception is property received by gift during the inventor's life. A gift recipient takes the inventor's basis but does not become a "holder" under Section 1235 unless they otherwise qualify. Gifting a patent to your child before reduction to practice may preserve some Section 1235 treatment for the child if the child paid consideration; outright gifts generally do not.
Common Mistakes That Sink the Deduction
A handful of recurring errors show up in audits and tax court cases:
The exclusive license that wasn't. A patent owner grants an "exclusive license" but retains the right to manufacture for one specific customer. That single carve-out is enough to defeat Section 1235 because the grantor has not transferred all the rights.
The field-of-use deal. A medical device inventor grants rights for the orthopedic market, retaining rights for cardiac applications. Even if orthopedic is the only realistic market, the field-of-use limit kills capital gain treatment.
The holding entity problem. The inventor forms an S corporation and assigns the patent to it before selling. The S corp now owns the patent, but the S corp is not an individual—so Section 1235 does not apply to the corporation's sale. The inventor's tax treatment ran out the moment the patent left individual hands.
The improvement patent issue. Inventor sells the original patent but retains rights to any improvements. The regulations look at improvements separately, so this can work—but only if the improvements are genuinely separate inventions, not derivative claims of the same patent family.
The 1099 trap. Inventor receives a 1099-MISC reporting royalties, panics, and reports the income on Schedule E. The mistake locks in ordinary treatment, and the IRS rarely lets taxpayers amend their way out of self-inflicted characterizations.
Why This Matters for Tax Planning
For most inventors, Section 1235 is the single biggest tax planning lever they will ever pull. The difference between ordinary income at 37% (federal, plus state and self-employment tax) and long-term capital gain at 20% (federal, plus state, no SE tax) can easily approach 25 percentage points of effective rate. On a million-dollar deal, that is $250,000 in real cash.
Even modest licensing transactions benefit. A working-class inventor with a $200,000 patent sale saves roughly $40,000 to $50,000 by structuring the deal as a Section 1235 sale instead of an ongoing license. The cost of doing it correctly is a few thousand dollars in legal review of the assignment agreement.
The decision is rarely whether to use Section 1235—it is almost always whether you can structure the deal in a way that qualifies. Buyers sometimes want narrower rights than the full patent provides, and that genuine commercial preference may force a license structure. In those cases, the parties can sometimes negotiate a sale of the relevant claims, or even a sale of a divisional patent, to bring the deal within Section 1235 for the seller.
Tax planning for inventors often starts long before there is anything to sell. The choice of entity, the timing of the patent application, the structure of any early investment, and the drafting of any operating agreement among co-inventors all influence whether Section 1235 will be available years later when a buyer appears. Working with a tax advisor in the prototype stage is far cheaper than untangling a mistake at closing.
Keep Your Inventor Income Organized from Day One
Tax planning around Section 1235 only works if you can document the entire chain—out-of-pocket research costs, prosecution fees, prototype expenses, partial assignments, and the eventual sale or licensing income. Inventors who track these costs in a clean, version-controlled ledger have a much easier time substantiating their basis, defending their characterization on audit, and showing the IRS that the transaction was structured the way the contract says it was.
Beancount.io provides plain-text accounting that gives inventors, founders, and freelance researchers complete transparency over their financial records. Every dollar of patent prosecution cost, every receipt for prototype materials, and every royalty check is recorded in a format you can audit, version, and share with your tax advisor without surrendering control. Get started for free and see why people who care about their data are switching to plain-text accounting.